Back

The comparison of composite end-points between SGLT-2 inhibitors and placebo in diabetic patients with heart failure with mildly reduced ejection fraction: a meta-analysis of the literature

29 August 2022 (09:15 - 09:45)
Organised by:
Congress Presentation Part of: Chronic heart failure - SGLT2i Heart Failure with Mid-Range Ejection Fraction (HFmrEF) ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Associate Professor Tufan Cinar

Sultan Abdulhamid Han Training and Research Hospital, Istanbul (Turkiye)

4 More presentations in this session

Presentation thumbnail
Cardiac sodium/hydrogen exchanger (NHE11) as a novel potential target for SGLT2i in heart failure
Doctor I. Gimenez Escamilla (Valencia, ES)
Abstract Slides
Presentation thumbnail
SGLT2 inhibitors in real-world patients with heart failure with preserved ejection fraction
Doctor R. Tarantini (Utrecht, NL)
Abstract Slides
Presentation thumbnail
Safety and efficacy of SGLT2 inhibitors in diabetic and non-diabetic heart failure patients, a meta-analysis of randomized controlled trials
Doctor A. Awad (Texas City, US)
Abstract Slides
Presentation thumbnail
SGLT2i uptake among heart failure patients with reduced ejection fraction: ongoing prescriber hesitancy and how to address this.
Doctor B. Soh (Galway, IE)
Abstract Slides

Access the full session

Session thumbnail
Chronic heart failure - SGLT2i

The Event

Event poster

ESC Congress 2022

29 August 2022 09:15 CET
You may be interested in
thumbnail
Congress Session
Meet the Experts: summation of the science - treatment of chronic heart failure in 2023
thumbnail
Webinar
Advanced heart failure therapy in HF patients with preserved and mildly reduced ejection fraction
thumbnail
Congress Presentation
Audience Q&A

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources